{"id":"W4412555545","doi":"10.1016/s0140-6736(25)00681-6","title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Royal Adelaide Hospital Research Fund; Genentech; Sun Pharma; Bristol-Myers Squibb; Royal Adelaide Hospital; Eli Lilly and Company; Gastroenterological Society of Australia; Mitsubishi Tanabe Pharma Corporation; Celltrion; Boston Pharmaceuticals; Kissei; Mylan; Boston Scientific Corporation; Leona M. and Harry B. Helmsley Charitable Trust; Teva Pharmaceutical Industries; EA Pharma Co., Ltd.; Gilead Sciences; Kyorin Pharmaceutical; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Allergan; AstraZeneca","keywords":"Medicine; Placebo; Crohn's disease; Ustekinumab; Randomization; Regimen; Internal medicine; Clinical trial; Surgery; Randomized controlled trial; Subcutaneous injection; Disease; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002208699,0.0011226,0.003624622,0.0003507869,0.0003195763,0.0009874001,0.001034984,0.002207002,0.0034191],"category_scores_gemma":[0.002155072,0.0006660193,0.002331197,0.0004246967,0.001449256,0.001399163,0.0003869278,0.003501719,0.0007837442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007569621,"about_ca_system_score_gemma":0.0007347801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006720014,"about_ca_topic_score_gemma":0.00105186,"domain_scores_codex":[0.9992024,0.0003750313,0.00007299257,0.0001341039,0.00007692029,0.0001384514],"domain_scores_gemma":[0.9985114,0.000509656,0.0004349028,0.0001449846,0.00006821019,0.0003308727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9617594,0.002541191,0.0007484087,0.0007200511,0.0008770528,0.00002589157,0.00004973366,0.0001967775,0.003864927,0.00004755118,0.0003340028,0.02883499],"study_design_scores_gemma":[0.8990221,0.09333833,0.005160458,0.00005869898,0.0007967229,0.00005783078,0.00002940646,0.0002588123,0.0007510735,0.00008253651,0.0004223151,0.00002172871],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818293,0.01463186,0.0004750938,0.0004984549,0.0002355748,0.0005931194,0.0005780193,0.00009429874,0.001064216],"genre_scores_gemma":[0.990858,0.00453619,0.0009010793,0.0006328745,0.0002882528,0.000798006,0.0008203923,0.00002162993,0.001143585],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003624622,"threshold_uncertainty_score":0.01168084,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02254636057427786,"score_gpt":0.290597861599281,"score_spread":0.2680515010250031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}